Durvalumab Plus Tremelimumab

DRUG3 trials

Sponsors

Samsung Medical Center, UNICANCER, Faculty of Medicine Siriraj Hospital, Mahidol University

Conditions

Head and Neck Squamous Cell CarcinomaHepatocellular CarcinomaUnresectable hepatocellular carcinoma Advanced hepatocellular carcinoma Liver cancer Carcinoma, Hepatocellular Liver Neoplasms Immunotherapy Immune Checkpoint Inhibitors Durvalumab Tremelimumab Portal Vein Thrombosis Expanded Access Programs

Phase 2

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Samsung Medical CenterHead and Neck Squamous Cell Carcinoma

Start: 2018-04-11End: 2022-03-31Updated: 2021-08-10

Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

RecruitingNCT06904170

UNICANCERHepatocellular Carcinoma

Start: 2025-11-14End: 2030-09-01Target: 196Updated: 2026-02-03

Unknown Phase

Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-world Multicenter Observational Study

Active, not recruitingTCTR20260314001

Faculty of Medicine Siriraj Hospital, Mahidol UniversityUnresectable hepatocellular carcinoma Advanced hepatocellular carcinoma Liver cancer Carcinoma, Hepatocellular Liver Neoplasms Immunotherapy Immune Checkpoint Inhibitors Durvalumab Tremelimumab Portal Vein Thrombosis Expanded Access Programs

Start: 2023-08-01Target: 50Updated: 2026-08-03

Related Papers

Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2021-05-204 citations